Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:...